Kira Gordon and Matt Majewski recently authored an article in MedTech Strategist discussing how hospital consolidation is increasing purchasing leverage through greater pricing transparency and that has substantiated a need for new pricing models in medtech. There are challenges associated with several emerging pricing models; regardless, manufacturers will need to develop innovative approaches to maximize opportunity while minimizing risk.
The end of high drug prices? Exploring the potential and limits of PDABs
Certain states in the US have enacted or are actively considering legislation to create PDABs, Prescription Drug Affordability Boards. PDABs are independent...